Its ability to drastically reduce Survivin protein contents in a mutational load-independent fashion enhances TH301 potential to cause PDAC apoptosis and supports its usefulness in novel, promising, and powerful regimens for pancreatic cancer chemotherapy. This evidence concerns the gene BIRC5 and familial pancreatic carcinoma.